<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02472795</url>
  </required_header>
  <id_info>
    <org_study_id>AC-064A201</org_study_id>
    <nct_id>NCT02472795</nct_id>
  </id_info>
  <brief_title>Clinical Study to Investigate the Biological Activity, Safety, Tolerability, and Pharmacokinetics of ACT-334441 in Subjects With Systemic Lupus Erythematosus</brief_title>
  <official_title>A Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-response Study to Investigate the Biological Activity, Safety, Tolerability, and Pharmacokinetics of ACT-334441 in Subjects With Systemic Lupus Erythematosus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Actelion</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Actelion</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      International trial to evaluate the biological activity and safety of ACT-334441 in lupus
      patients.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 1, 2015</start_date>
  <completion_date type="Actual">February 1, 2017</completion_date>
  <primary_completion_date type="Actual">February 1, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in total lymphocyte count from baseline to End of Treatment (EOT)</measure>
    <time_frame>Baseline to End of Treatment (EOT) (12 weeks)</time_frame>
    <description>Total lymphocyte count at EOT minus total lymphocyte count at baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Treatment-emergent adverse events (including serious adverse events)</measure>
    <time_frame>Baseline to End of Study (EOS) (18 weeks) / Follow-up</time_frame>
    <description>Treatment-emergent AEs (and SAEs) from first study treatment intake up to 6 weeks (inclusive) after last study treatment intake</description>
  </primary_outcome>
  <other_outcome>
    <measure>ACT-334441 plasma concentration</measure>
    <time_frame>Baseline to End of Treatment (EOT) (12 weeks) and End of Study (EOS) (18 weeks)</time_frame>
    <description>Ctrough ACT-334441 plasma concentrations prior to dosing at each study visits until EOS</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in disease activity (SLEDAI-2K)</measure>
    <time_frame>Baseline to End of Treatment (EOT) (12 weeks) and End of Study (EOS) (18 weeks)</time_frame>
    <description>Change in SLEDAI-2K score from baseline to each post-baseline assessments</description>
  </other_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">64</enrollment>
  <condition>Systemic Lupus Erythematosus</condition>
  <arm_group>
    <arm_group_label>Investigational treatment - 0.5mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ACT-334441 0.5 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Investigational treatment - 1mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ACT-334441 1 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Investigational treatment - 2mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ACT-334441 2 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Investigational treatment - 4mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ACT-334441 4 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>administered orally</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo matching ACT-334441 capsules or Experimental doses</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ACT-334441</intervention_name>
    <description>Selective Sphingosine 1-phosphate (S1P) modulator</description>
    <arm_group_label>Investigational treatment - 4mg</arm_group_label>
    <arm_group_label>Investigational treatment - 0.5mg</arm_group_label>
    <arm_group_label>Investigational treatment - 1mg</arm_group_label>
    <arm_group_label>Investigational treatment - 2mg</arm_group_label>
    <other_name>Cenerimod</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female subjects aged 18 to 65 years with established SLE. Subjects must have
             active SLE, Systemic Lupus Erythematosus Disease Activity Index-2000 (SLEDAI-2K) score
             of at least 2 points for musculoskeletal or mucocutaneous manifestations and history
             or presence at Screening of positive anti-nuclear antibodies (ANA) or
             anti-double-stranded DNA (anti-dsDNA) antibodies.

          -  Enrolled subjects must be treated with background SLE medications.

        Exclusion Criteria:

          -  Subjects with significant medical conditions or therapies for such conditions (e.g.,
             cardiovascular, pulmonary, immunological, hepatic, ophthalmological, infection and
             infection risks, history or presence of malignancy, history or presence of bone marrow
             or solid organ transplantation) or lactating or pregnant women.

          -  Subjects with severe SLE disease or with clinically relevant medical or surgical
             conditions that, in the opinion of the investigator, would put the subject at risk by
             participating in the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Anniston</city>
        <state>Alabama</state>
        <zip>36207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33765</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Minsk</city>
        <zip>220116</zip>
        <country>Belarus</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Minsk</city>
        <zip>223041</zip>
        <country>Belarus</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Vitebsk</city>
        <zip>210037</zip>
        <country>Belarus</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Plovdiv</city>
        <zip>4000</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Plovdiv</city>
        <zip>4002</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Sofia</city>
        <zip>1612</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Tbilisi</city>
        <zip>0186</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Kemerovo</city>
        <zip>650066</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Kursk</city>
        <zip>305007</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Omsk</city>
        <zip>644111</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Orenburg</city>
        <zip>460018</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Smolensk</city>
        <zip>214025</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Vladimir</city>
        <zip>600023</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Vinnytsya</city>
        <zip>21018</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Vinnytsya</city>
        <zip>21029</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Zaporizhia</city>
        <zip>69600</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belarus</country>
    <country>Bulgaria</country>
    <country>Georgia</country>
    <country>Russian Federation</country>
    <country>Ukraine</country>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 14, 2015</study_first_submitted>
  <study_first_submitted_qc>June 12, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 16, 2015</study_first_posted>
  <disposition_first_submitted>February 20, 2018</disposition_first_submitted>
  <disposition_first_submitted_qc>February 20, 2018</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">February 22, 2018</disposition_first_posted>
  <last_update_submitted>March 2, 2018</last_update_submitted>
  <last_update_submitted_qc>March 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 5, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Systemic lupus erythematosus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lupus Erythematosus, Systemic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

